Herceptin causes flu-like symptoms in about 40% of the people who take it. These symptoms may include:
Side effects generally become less severe after the first treatment. Your treatment team will monitor you during your infusions, especially your first dose, and can adjust the infusion if you are very uncomfortable. If you are receiving Herceptin every 3 weeks, you may have stronger side effects.
If you are receiving Herceptin with chemotherapy, you may also experience chemotherapy side effects.
Less commonly, Herceptin can damage the heart's ability to pump blood effectively. Rarely (about 5% of the time), the heart damage is bad enough that people experience stroke or life-threatening congestive heart failure -- a condition in which the heart can't pump effectively. Slightly more often (about 7% of the time), Herceptin causes mild heart failure.
Women who experience mild or more serious heart damage can stop taking Herceptin and start taking heart-strengthening medications. This often brings heart function back to normal.
Heart damage can be more severe when Herceptin is given along with other chemotherapy medicines known to cause heart damage, including Adriamycin. Taking Herceptin with the chemotherapy drug Taxol does not increase your risk of severe heart damage. Studies have shown that this combination causes only slightly more mild heart damage than Herceptin alone.
Before starting Herceptin therapy, you should have an echocardiogram or a MUGA (multigated blood-pool imaging) scan to check how well your heart is functioning.
When you first start taking Herceptin, your doctor might want you to have MUGA scans or echocardiograms every few months to detect any sign of heart failure. But after you've been on Herceptin for a while, you may need a heart-monitoring test only every 6 months or so. This is because heart failure is less likely to occur the longer you take Herceptin.
Notify your doctor immediately or go to the nearest emergency room if you're taking Herceptin and you develop any symptoms of heart failure, such as shortness of breath, difficulty breathing, a fast or irregular heartbeat, increased cough, and swelling of the feet or lower legs.
Herceptin can very rarely cause two serious reactions that interfere with your breathing: allergy-like reactions and lung reactions. Symptoms of the allergy-like reactions include hives, wheezing, and trouble breathing because of swelling and muscle spasms of the airways. Lung reactions include swelling of the lung, low blood pressure, or fluid buildup around the lungs (called pleural effusions).
The risk of these life-threatening reactions is rare, much less than 1%. In most cases, this reaction happened within the first 24 hours of the first dose of Herceptin. The rest of the time, it usually happened within the first week of the first dose. Only occasionally did reactions occur with the second or later doses. The lung reactions are more severe if you've already had lung disease, such as asthma or emphysema, or if the breast cancer has spread significantly into your lungs. If you are currently undergoing treatment with Herceptin and have been tolerating it well, you're unlikely to develop these serious reactions.
Even though the severe side effects are relatively rare, your doctor should check you carefully for any heart or lung problems before starting to treat you with Herceptin. You should also be monitored closely for these serious side effects during treatment.
An original video-on-demand educational initiative brought to you by Breastcancer.org and Comcast. Visit www.comcast.net/pinkribbon each week through the end of October for engaging, up-to-date videos and information about the fight to end breast cancer.
Breastcancer.org 7 East Lancaster Avenue, 3rd Floor Ardmore, PA 19003
Learn more about our commitment to your privacy
© 2008 Breastcancer.org - All rights reserved.
Breastcancer.org is a non-profit organization dedicated to providing information and community to those touched by this disease. Learn more about our commitment to providing complete, accurate, and private breast cancer information.